Lozap Plus, 50 mg+12, 5 mg 60 pcs

Edema, Prevention of heart attacks and strokes, Hypertension (high blood pressure) – Arterial hypertension (in patients for whom the combination therapy is optimal);
– Reducing the risk of cardiovascular disease and mortality in patients with arterial hypertension and left ventricular hypertrophy.

Indications

– Arterial hypertension (in patients for whom combination therapy is optimal);
– Reducing the risk of cardiovascular disease and mortality in patients with arterial hypertension and left ventricular hypertrophy.

Pharmacological effect

PHARMACOTHERAPEUTIC GROUP

Special instructions

LOZAP PLUS can be prescribed together with other antihypertensive drugs.

Active ingredient

Hydrochlorothiazide, Losartan

Composition

1 film-coated tablet contains active substances:

Losartan potassium 50 mg and hydrochlorothiazide 12.5 mg

Excipients

Mannitol,

microcrystalline cellulose,

croscarmellose sodium,

povidone,

magnesium stearate,

hypromellose 2910/5,

macrogol 6000,

talc,

simethicone emulsion,

Opaspray yellow M-1-22801 (which contains: purified water, titanium dioxide, denatured ethanol (methylated alcohol BP) (99% ethanol: 1% methanol), hypromellose, Quinoline Yellow dye (E 104), Crimson dye [Ponceau 4R] (Pounceau 4R) (E 124)).

DESCRIPTION

Oblong, light yellow, film-coated tablets with a halving score on both sides.

Contraindications

– hypersensitivity to the components of the drug;
– anuria;
– severe arterial hypotension;
– severe dysfunction of the liver and kidneys (creatinine clearance ≥ 30 ml/s);
– hypovolemia (including against the background of high doses of diuretics);
– pregnancy and lactation period;
– age under 18 years (efficacy and safety have not been established).

Use with caution in patients with bilateral renal stenosis or stenosis of the artery of a single kidney.
The drug is prescribed with caution in patients with diabetes mellitus, hypercalcemia, hyperuricemia and/or gout, as well as patients with a history of allergy and bronchial asthma, as well as systemic connective tissue diseases (including systemic lupus erythematosus).

Side Effects

Adverse reactions are limited to those previously observed with the use of losartan potassium and/or hydrochlorothiazide. The most common side effects in the treatment of essential hypertension include dizziness.

Interaction

Losartan enhances the effect of other antihypertensive drugs. There was no clinically significant interaction with hydrochlorothiazide, digoxin, indirect anticoagulants, cimetidine, phenobarbital, ketokenazole, erythromycin. As with other drugs that block angiotensin II or its action, concomitant administration of potassium-sparing diuretics (eg, spironolactone, triamterene, amiloride), potassium supplements, or potassium-containing salt substitutes may result in hyperkalemia.

Overdose

Symptoms: losartan – marked decrease in blood pressure, tachycardia, bradycardia (as a result of vagal stimulation). Hydrochlorothiazide – loss of electrolytes (hypokalemia, hyperchloremia, hyponatremia), as well as dehydration resulting from excess diuresis.

Storage conditions

List B.

Shelf life

3 years.

Manufacturer

Zentiva k.s., Czech Republic